Recent Patents on Anti-Cancer Drug Discovery This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

UBE2L3 Promotes Oxidative Stress-regulated Necroptosis to Accelerate Osteosarcoma Progression
CONCLUSION: UBE2L3 is upregulated in osteosarcoma cells, and silencing of UBE2L3 promotes oxidative stress in these cells, leading to enhanced necroptosis and delayed progression of osteosarcoma.PMID:38385491 | DOI:10.2174/0115748928297557240212112531 (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - February 22, 2024 Category: Cancer & Oncology Authors: Xiwu Zhao Guoqiang Shan Deguo Xing Hongwei Gao Zhenggang Xiong Wenpeng Hui Mingzhi Gong Source Type: research

Survival Benefits of Ganoderma Lucidum in Early-stage Triple-negative Breast Cancer: A Real World Study
CONCLUSIONS: The results of this real-world propensity-score-matched study suggest that GLSP can improve OS and DFS in early-stage TNBC patients. A higher OS was observed for patients taking GLSP, particularly in stage II and stage III.PMID:38385492 | DOI:10.2174/0115748928282946240111114448 (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - February 22, 2024 Category: Cancer & Oncology Authors: Baohong Jiang Na Li Wei Du Lijun Zeng Yuanbin Tang Lunqi Luo Hongbo Zhu Feng Ye Source Type: research

Metformin Inhibits NLRP3 Inflammasome Expression and Regulates Inflammatory Microenvironment to Delay the Progression of Colorectal Cancer
CONCLUSION: Metformin can inhibit the expression of NLRP3 inflammasome, thereby suppressing the expression of inflammation-related factors, reducing the damage of the inflammatory microenvironment to normal cells, and delaying the progression of colorectal cancer.PMID:38347775 | DOI:10.2174/0115748928274081240201060643 (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - February 13, 2024 Category: Cancer & Oncology Authors: Gaojie Liu Feixiang Wang Yanlin Feng Hongsheng Tang Source Type: research

Mechanisms of Anti-PD Therapy Resistance in Digestive System Neoplasms
Recent Pat Anticancer Drug Discov. 2024 Jan 4. doi: 10.2174/0115748928269276231120103256. Online ahead of print.ABSTRACTDigestive system neoplasms are highly heterogeneous and exhibit complex resistance mechanisms that render anti-programmed cell death protein (PD) therapies poorly effective. The tumor microenvironment (TME) plays a pivotal role in tumor development, apart from supplying energy for tumor proliferation and impeding the body's anti-tumor immune response, the TME actively facilitates tumor progression and immune escape via diverse pathways, which include the modulation of heritable gene expression alterations...
Source: Recent Patents on Anti-Cancer Drug Discovery - February 2, 2024 Category: Cancer & Oncology Authors: Yuxia Wu Xiangyan Jiang Zeyuan Yu Zongrui Xing Yong Ma Huiguo Qing Source Type: research

Regulating Lipid Metabolism via Mitochondrial Dynamics in Tongue Squamous Cell Carcinoma Cancer Stem Cells
CONCLUSION: This study provides a deeper insight into the alterations of lipid metabolism associated with TSCC CSCs, non-CSCs and CSCs regulated by mitochondrial dynamics and thus serves as a guide toward novel targeted therapies.PMID:38305307 | DOI:10.2174/0115748928275772231226063458 (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - February 2, 2024 Category: Cancer & Oncology Authors: Fan Wu Suling Chen Siqi Ren Ruixin Wang Yongmei Tan Rongxi Chen Bowen Li Haotian Cao Jinsong Li Source Type: research

SSPH I, A Novel Anti-cancer Saponin, Inhibits EMT and Invasion and Migration of NSCLC by Suppressing MAPK/ERK1/2 and PI3K/AKT/mTOR Signaling Pathways
CONCLUSION: SSPH I inhibited EMT, migration, and invasion of NSCLC cells by suppressing MAPK/ERK1/2 and PI3K/AKT/mTOR signaling pathways, suggesting that the natural compound SSPH I could be used for inhibiting metastasis of NSCLC.PMID:38305308 | DOI:10.2174/0115748928283132240103073039 (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - February 2, 2024 Category: Cancer & Oncology Authors: Jinling Zhou Jian Luo Rizhi Gan Limin Zhi Huan Zhou Meixian Lv Yinmei Huang Gang Liang Source Type: research

TPD52 as a Potential Prognostic Biomarker and its Correlation with Immune Infiltrates in Uterine Corpus Endometrial Carcinoma: Bioinformatic Analysis and Experimental Verification
CONCLUSION: TPD52 is upregulated in UCEC and may be a useful patent for prognostic biomarkers of UCEC, which may have important value for clinical treatment and supervision of UCEC patients.PMID:38305309 | DOI:10.2174/0115748928267447231107101539 (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - February 2, 2024 Category: Cancer & Oncology Authors: Lu Miao Buze Chen Li Jing Tian Zeng Youguo Chen Source Type: research

Screening of Candidate Inflammatory Markers of Epithelial Cells in Hepatocellular Carcinoma Based on Integration Analysis of TCGA/ICGC Databases and Single-cell Sequencing
CONCLUSION: Inflammatory factors CCL7, GPR132, ITGB8, PTAFR, SELL, and VIP influence the inflammatory cascade response in HCC epithelial cells, and their expression correlates with the survival prognosis of HCC patients. Interfering with VIP expression effectively suppresses proliferation, migration, and invasion of HCC cells, as well as inhibiting the occurrence of inflammatory cascade reactions, thus slowing down the progression of hepatocellular carcinoma. Furthermore, compounds NADH and Deferoxamine have the potential to target and bind to the inflammatory protein VIP, highlighting their relevance in potential HCC trea...
Source: Recent Patents on Anti-Cancer Drug Discovery - February 1, 2024 Category: Cancer & Oncology Authors: Zupin Huang Zhuokai Li Xinliang Lv Wei Tan Source Type: research

Statin Use and Hepatocellular Carcinoma Risk: A Comprehensive Meta- Analysis and Systematic Review
CONCLUSION: This meta-analysis found statin use is associated with a significantly lower HCC risk. Statins may be a promising preventive intervention against HCC.PMID:38284728 | DOI:10.2174/0115748928282686231221070441 (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - January 29, 2024 Category: Cancer & Oncology Authors: Mahmood Reza Hashemi Rafsanjani Rasoul Rahimi Saeid Heidari-Soureshjani Mohammad Darvishi Omid-Ali Adeli Saber Abbaszadeh Source Type: research

Updated Progress on Mass Spectrometry Imaging and its Application in Cancer Treatment and Drug Discovery
CONCLUSION: MSI is a convenient, fast and powerful technology that has made great progress in sample preparation, instrumentation, quantitation, and multimodal imaging. MSI has emerged as a powerful technique in various biomedical applications, which has strong potential in cancer detection, treatment, formation mechanism research, discovery of biomarkers, and drug discovery process.PMID:38275033 | DOI:10.2174/0115748928269691231203164021 (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - January 26, 2024 Category: Cancer & Oncology Authors: Mingyue Li Jingna Zhou Tingting Zhang Jingyang Lu Yajie Wang Junyu Liu Xiaoyu Zhang Haixia Chen Source Type: research